How does this proposed therapy compare with simply reducing the amount of carbidopa taken by PwP?

AADC is found in both the body and in the brain, so I suspect, but don't know, that it crosses the BBB.

Sinemet contains both levodopa and carbidopa, usually in a ratio by weight of 4:1, but a 10:1 variant also exists. Carbidopa is an AADC inhibitor. It does not cross the BBB.

Reducing the ADDC inhibitor is likely, therefore, to increase ADDC levels in the brain. This is the intent of the new therapy also.

It seems to me that a better approach is to find, for each PwP, what ratio of carbidopa best suits them individually.

John